Sientra (SIEN) vs. MiMedx Group (MDXG) Critical Comparison

Sientra (NASDAQ: SIEN) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares Sientra and MiMedx Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sientra -169.77% -68.82% -43.13%
MiMedx Group 11.64% 17.49% 12.69%

Analyst Recommendations

This is a summary of current recommendations and price targets for Sientra and MiMedx Group, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sientra 0 1 4 0 2.80
MiMedx Group 1 0 3 0 2.50

Sientra currently has a consensus price target of $13.75, suggesting a potential downside of 9.90%. MiMedx Group has a consensus price target of $17.00, suggesting a potential upside of 36.00%. Given MiMedx Group’s higher possible upside, analysts clearly believe MiMedx Group is more favorable than Sientra.

Institutional and Insider Ownership

76.6% of Sientra shares are owned by institutional investors. Comparatively, 69.4% of MiMedx Group shares are owned by institutional investors. 28.1% of Sientra shares are owned by insiders. Comparatively, 12.4% of MiMedx Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Sientra has a beta of -1.47, suggesting that its stock price is 247% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.

Earnings and Valuation

This table compares Sientra and MiMedx Group’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sientra $20.73 million 14.28 -$40.16 million ($2.85) -5.35
MiMedx Group $245.01 million 5.67 $11.97 million $0.31 40.32

MiMedx Group has higher revenue and earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Summary

MiMedx Group beats Sientra on 8 of the 13 factors compared between the two stocks.

About Sientra

Sientra, Inc. is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. Its breast implants are primarily used in elective procedures, which are generally performed on a cash-pay basis. TRUE Texture provides texturing on the implant shell that is designed to reduce the incidence of malposition, rotation and capsular contracture. The Company also offers breast tissue expanders and a range of other aesthetic and specialty products. The Company offers a range of HSC+ breast implants, including anatomically shaped textured, round textured and round smooth. The Company also offers miraDry system, the device to reduce underarm sweat, odor and permanently reduce hair of all colors.

About MiMedx Group

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply